What has FDA cited under 21 CFR 211.84(d)(1)?

1 DSRV article cite 21 CFR 211.84(d)(1). Enforcement cases behind them: Five coordinated FDA warning letters issued June 2, 2026, including WL 320-26-89 to Revlon Group Holdings (US), WL 320-26-90 to Shantou Qiwei Industry (China), WL 320-26-92 to Umendra Life Sciences and Zydus Lifesciences (India), and WL 320-26-87 to Laboratorios Dr. Collado (Dominican Republic), all citing 21 CFR 211.84(d). Inspection exposure across them: 1 high.

What does DSRV recommend for 21 CFR 211.84(d)(1)?

From the newest article (FDA Found Zero Asbestos Testing at Five OTC Manufacturers): Inspection readiness now includes records readiness: what the component testing file shows on any given day is the compliance evidence FDA can request without warning, without a site visit, and without regard to the last inspection outcome. DSRV is decision support, not legal advice; verify against the official source each article names.

Browse by regulation1 article · 1 high

21 CFR 211.84(d)(1)

Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.84(d)(1): the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set

What has FDA cited under 21 CFR 211.84(d)(1)?: 1 DSRV article cite 21 CFR 211.84(d)(1). Enforcement cases behind them: Five coordinated FDA warning letters issued June 2, 2026, including WL 320-26-89 to Revlon Group Holdings (US), WL 320-26-90 to Shantou Qiwei Industry (China), WL 320-26-92 to Umendra Life Sciences and Zydus Lifesciences (India), and WL 320-26-87 to Laboratorios Dr. Collado (Dominican Republic), all citing 21 CFR 211.84(d). Inspection exposure across them: 1 high.
What does DSRV recommend for 21 CFR 211.84(d)(1)?: From the newest article (FDA Found Zero Asbestos Testing at Five OTC Manufacturers): Inspection readiness now includes records readiness: what the component testing file shows on any given day is the compliance evidence FDA can request without warning, without a site visit, and without regard to the last inspection outcome. DSRV is decision support, not legal advice; verify against the official source each article names.

June 20267 min readHigh exposurecited as a tag
FDA Found Zero Asbestos Testing at Five OTC Manufacturers
On June 2, 2026, FDA issued five coordinated warning letters to OTC drug manufacturers across four countries for the same CGMP failure, without a single on-site inspection. The violation is straightforward. What the enforcement mechanism reveals is not.
Case
Five coordinated FDA warning letters issued June 2, 2026, including WL 320-26-89 to Revlon Group Holdings (US), WL 320-26-90 to Shantou Qiwei Industry (China), WL 320-26-92 to Umendra Life Sciences and Zydus Lifesciences (India), and WL 320-26-87 to Laboratorios Dr. Collado (Dominican Republic), all citing 21 CFR 211.84(d).
DSRV take
Inspection readiness now includes records readiness: what the component testing file shows on any given day is the compliance evidence FDA can request without warning, without a site visit, and without regard to the last inspection outcome.

Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under 21 CFR 211.84(d)(1). DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about 21 CFR 211.84(d)(1)

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.